Immediate Infusion Reaction to Intravenous Ustekinumab in Three Crohn's Disease Patients: A Case Report and Review of the Literature

被引：3

作者：

Thomas, Pepijn W. A. ^{[1
]}

Ferwerda, Gerben ^{[2
]}

West, Rachel L. ^{[3
]}

Hoentjen, Frank ^{[1
]}

机构：

[1] Radboud Univ Nijmegen, Dept Gastroenterol & Hepatol, Med Ctr, POB 9101,Code 455, NL-6500 HB Nijmegen, Netherlands

[2] Radboud Inst Mol Life Sci, Sect Paediat Infect Dis, Lab Med Immunol, Nijmegen, Netherlands

[3] Franciscus Gasthuis & Vlietland, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands

来源：

JOURNAL OF CROHNS & COLITIS | 2021年 / 15卷 / 01期

关键词：

Ustekinumab; Crohn's disease; infusion reaction;

D O I：

10.1093/ecco-jcc/jjaa115

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Recently, ustekinumab has been approved for the treatment of Crohn's disease and ulcerative colitis.Treatment is started with an intravenous induction dose, followed by a subcutaneous dosage. We present details of three patients with therapy-refractory Crohn's disease who experienced an immediate infusion reaction to intravenous administration of ustekinumab. In two of these patients a subsequent reaction to subcutaneous injections occurred. Clinical features and pathophysiology are discussed.

引用

页码：162 / 164

页数：3

共 15 条

[1] Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose
Chung, Christine H.
Mirakhur, Beloo
Chan, Emily
Le, Quynh-Thu
Berlin, Jordan
Morse, Michael
Murphy, Barbara A.
Satinover, Shama M.
Hosen, Jacob
Mauro, David
Slebos, Robbert J.
Zhou, Qinwei
Gold, Diane
Hatley, Tina
Hicklin, Daniel J.
Platts-Mills, Thomas A. E.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (11) : 1109 - 1117
[2] Cleveland NK, 2018, AM J GASTROENTEROL, V113, pS1168
[3] Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
Feagan, B. G.
Sandborn, W. J.
Gasink, C.
Jacobstein, D.
Lang, Y.
Friedman, J. R.
Blank, M. A.
Johanns, J.
Gao, L. -L.
Miao, Y.
Adedokun, O. J.
Sands, B. E.
Hanauer, S. B.
Vermeire, S.
Targan, S.
Ghosh, S.
de Villiers, W. J.
Colombel, J. -F.
Tulassay, Z.
Seidler, U.
Salzberg, B. A.
Desreumaux, P.
Lee, S. D.
Loftus, E. V., Jr.
Dieleman, L. A.
Katz, S.
Rutgeerts, P.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (20) : 1946 - 1960
[4] IgE and mast cells in allergic disease
Galli, Stephen J.
Tsai, Mindy
[J]. NATURE MEDICINE, 2012, 18 (05) : 693 - 704
[5] SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis
Goncalves, Joao
Myung, Gihyun
Park, MinJeong
Jeong, Deokyoon
Ghil, Jeehoon
[J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2019, 12
[6] B cell epitopes on infliximab identified by oligopeptide microarray with unprocessed patient sera
Homann, Arne
Roeckendorf, Niels
Kromminga, Arno
Frey, Andreas
Jappe, Uta
[J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13
[7] Infliximab-Related Infusion Reactions: Systematic Review
Lichtenstein, Lev
Ron, Yulia
Kivity, Shmuel
Ben-Horin, Shomron
Israeli, Eran
Fraser, Gerald M.
Dotan, Iris
Chowers, Yehuda
Confino-Cohen, Ronit
Weiss, Batia
[J]. JOURNAL OF CROHNS & COLITIS, 2015, 9 (09) : 806 - 815
[8] Acute infusion reactions induced by monoclonal antibody therapy
Maggi, Enrico
Vultaggio, Alessandra
Matucci, Andrea
[J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2011, 7 (01) : 55 - 63
[9] Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?
Murdaca, Giuseppe
Spano, Francesca
Contatore, Miriam
Guastalla, Andrea
Penza, Elena
Magnani, Ottavia
Puppo, Francesco
[J]. EXPERT OPINION ON DRUG SAFETY, 2016, 15 (01) : 43 - 52
[10] Systemic allergy to EDTA in local anesthetic and radiocontrast media
Russo, Paul Anthony John
Banovic, Tatjana
Wiese, Michael D.
Whyte, Andrew Francis
Smith, William Bernard
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2014, 2 (02) : 225 - U273

← 1 2 →